Brainomix unveils positive findings from AstraZeneca clinical trial collaboration

Oxford medtech firm Brainomix has hailed the latest findings from its collaboration with pharma AstraZeneca on the latter's Phase 2 clinical trial of the drug Tralokinumab to treat the lung condition Idiopathic Pulmonary Fibrosis (IPF).
The data, which was published in the American journal of respiratory and critical care medicine, showed that Brainomix's e-Lung AI-enabled software could play a role in differentiating patients in trials most at risk of decline and outperformed current standard measures.
READ MORE: Stroke treatment access improved by Brainomix AI
The Brainomix tool is uniquely powered by the weighted reticulovascular score (WRVS) - a novel biomarker.
Dr Kristoffer Ostridge, the head of experimental medicine at AstraZeneca, commented on the value of the Brainomix research partnership.
"As key components in AstraZeneca’s strategy to bring new medicines to patients faster and more effectively, data science and AI are transforming R&D.
"Our collaboration with Brainomix helped us to expand our understanding of the potential that innovative AI approaches can bring to improving the design of clinical trial for patients with Interstitial Lung Disease."
IPF is a condition in which people's lungs become scarred and breathing becomes increasingly difficult.
A spin-out from Oxford university, Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis.
It has offices in the UK, Ireland and the USA, and operations in more than 30 countries.
The collaboration with AstraZeneca was driven by Brainomix’s life sciences division.